Break-Point: FDA Committee Votes To Restrict Quinolones, But Does Not Endorse Disability Syndrome

One way of describing the Nov. 5 meeting of FDA’s Antimicrobial Drugs and Drug Safety & Risk Management Advisory Committees focused on a long-standing safety concern with a very widely used class of drugs.

Critics of the quinolone class—including Public Citizen—have advocated for labeling changes and product withdrawals for two decades, asserting that the...